-

KARL STORZ Granted Cybersecurity Authorization to Operate From U.S. Department of Defense

Three-Year Term Covers Operating Room Integration Solutions

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive surgical technology and operating room integration, has been granted an Authorization to Operate (ATO) by the U.S. Department of Defense (DoD), Defense Health Agency (DHA). This ATO, valid for three years, can be applied across all branches of the federal government, including the Army, Air Force, Navy, Marines, Coast Guard, and Veterans Health Administration as well as other agencies utilizing federally allocated dollars.

Cybersecurity is a key element in the successful implementation and deployment of any medical device, but especially integrated operating rooms. Technology products and suppliers that receive an ATO have cleared extensive IT security and privacy controls and undergo training that help prevent additional risk to government systems. This means KARL STORZ is deemed secure within certain deployment parameters and remains the only operating room integration supplier with an ATO from the DoD. This is, in fact, the second time that KARL STORZ has been granted an ATO—once under the previous DIACAP cybersecurity program, and now under the current Risk Management Framework (RMF).

“Our commitment to the Department of Defense is ongoing, and the product improvements we make will ultimately serve our customers across all government as well as nongovernment commercial sectors,” said Patrick Neely, Director of Federal Healthcare at KARL STORZ. “We provide advanced surgical technologies to the men and women defending our country, while also maintaining the cybersecurity of our nation. This means securing products to the highest cybersecurity standards so that clinical staff and patients have access to the most comprehensive surgical feature set during minimally invasive procedures.”

KARL STORZ Endoscopy-America, Inc., is an innovative leader in endoscopic technology and imaging solutions across virtually all surgical specialties. KARL STORZ provides solutions that facilitate operational and workflow efficiencies across various sites of care, so healthcare providers can deliver optimal patient care in the most cost-effective manner. The group is an affiliate of KARL STORZ SE & Co. KG, an international leader and family-owned company based in Germany that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, call 800-421-0837 or visit the company’s website at www.karlstorz.com.

Contacts

Susan Mancia
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8100

KARL STORZ Endoscopy-America, Inc.


Release Versions

Contacts

Susan Mancia
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8100

Social Media Profiles
More News From KARL STORZ Endoscopy-America, Inc.

ADDING MULTIMEDIA KARL STORZ Announces FDA Clearance for ENDOFLATOR + Insufflator and Smoke Evacuation System

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +. ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms. Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparos...

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development,...

AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to...
Back to Newsroom